GAPDH is very promising target for the treatment of a wide range of tumors, in contrast to other specific anticancer agents, such as Herceptin, which is used in the treatment of HER2-positive breast cancer only (Krasnov et al., 2013). The gene discussed is GAPDH; the disease is breast carcinoma.